Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Up 1,667.8% in August

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totaling 1,828,008 shares, an increase of 1,667.8% from the August 15th total of 103,406 shares. Approximately 1.5% of the shares of the company are short sold. Based on an average trading volume of 8,029,553 shares, the short-interest ratio is currently 0.2 days.

Institutional Investors Weigh In On Xtant Medical

Several large investors have recently bought and sold shares of XTNT. AWM Investment Company Inc. bought a new stake in shares of Xtant Medical during the second quarter worth $2,516,000. Renaissance Technologies LLC lifted its position in Xtant Medical by 7.3% in the 1st quarter. Renaissance Technologies LLC now owns 987,410 shares of the medical device company’s stock valued at $551,000 after acquiring an additional 67,550 shares in the last quarter. Wiregrass Investment Management LLC bought a new stake in Xtant Medical in the 4th quarter valued at $81,000. Tradition Wealth Management LLC acquired a new position in Xtant Medical in the 4th quarter worth $79,000. Finally, Hillsdale Investment Management Inc. acquired a new position in Xtant Medical in the 4th quarter worth $284,000. Institutional investors own 69.33% of the company’s stock.

Xtant Medical Price Performance

XTNT traded up $0.01 during midday trading on Thursday, hitting $0.34. The company had a trading volume of 376,122 shares, compared to its average volume of 710,290. Xtant Medical has a twelve month low of $0.27 and a twelve month high of $0.95. The company has a market capitalization of $48.25 million, a PE ratio of -4.30 and a beta of -0.15. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.05 and a current ratio of 2.16. The firm’s 50-day simple moving average is $0.39 and its 200-day simple moving average is $0.47.

Xtant Medical (NYSEAMERICAN:XTNT) last released its earnings results on Tuesday, August 11th. The medical device company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.05). Xtant Medical had a negative return on equity of 23.45% and a negative net margin of 10.17%.The firm had revenue of $23.03 million for the quarter, compared to the consensus estimate of $24.88 million.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on XTNT shares. Loop Capital set a $1.00 price objective on shares of Xtant Medical in a report on Wednesday, September 2nd. BTIG Research reissued a “buy” rating and issued a $1.00 target price on shares of Xtant Medical in a research note on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $1.00.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.